Using Synergistic Combination Drug Therapy to Battle Antibiotic Resistance
AUG 23, 2017 | CONTAGION® EDITORIAL STAFF
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, shares how his team’s research on the development of MRSA prodrug, TXA709, can help inform the development of novel drugs to treat other drug-resistant bacteria. Dr. LaVoie explains the benefits of synergistic drug combination and how this allows for fewer possibilities for resistance to develop.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512